Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 7/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.38 |
| ▸ | GSR | P00390 | 2/20 | 0.38 |
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16748191 | 0.84 | MAPT (0.40) | TXNRD1MAPTPIN1MERTKFGFR4 | |
| SCHEMBL796948 | 0.84 | MAPT (0.43) | TXNRD1MAPTPIN1MERTKFGFR4 | |
| SCHEMBL30866861 | 0.81 | S1PR4 (0.46) | TXNRD1MAPTPIN1GSR | |
| SCHEMBL15174972 | 0.81 | S1PR4 (0.46) | TXNRD1MAPTPIN1GSR | |
| SCHEMBL192421 | 0.77 | ALDH1A1 (0.53) | MAPTPIN1TDP1POLBL3MBTL1 | |
| SCHEMBL23878654 | 0.77 | MERTK (0.40) | MAPTPIN1MERTKFGFR4RPS6KB2 | |
| SCHEMBL1140984 | 0.71 | PTGES (0.38) | TXNRD1MAPTPIN1TDP1POLB | |
| SCHEMBL405386 | 0.71 | TSHR (0.47) | MAPTPOLB | |
| SCHEMBL29742161 | 0.71 | TSHR (0.47) | MAPTPOLB | |
| SCHEMBL14905208 | 0.70 | EGFR (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661531-A | Imidazolone compound as well as preparation method and application thereof | 北京富龙康泰生物技术有限公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-3072893-B1 | KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF | BEIJING FORELANDPHARMA CO LTD (CN) | 2020-03-18 | — | — | EP | disclosed |
| CN-104411706-B | Imidazolone derivatives, pharmaceutical compositions and uses thereof | 北京富龙康泰生物技术有限公司 | 2016-11-16 | — | — | CN | disclosed |
| US-20160304510-A1 | IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BEIJING FORELANDPHARMA CO. LTD. (CN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304510-A1 | IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BEIJING FORELANDPHARMA CO. LTD. (CN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304510-A1 | IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BEIJING FORELANDPHARMA CO. LTD. (CN) | 2016-10-20 | — | — | US | disclosed |
| EP-3072893-A1 | KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF | Beijing Forelandpharma Co. Ltd. (CN) | 2016-09-28 | — | — | EP | disclosed |
| EP-3072893-A1 | KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF | Beijing Forelandpharma Co. Ltd. (CN) | 2016-09-28 | — | — | EP | disclosed |
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| WO-2015074516-A1 | KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF | 北京富龙康泰生物技术有限公司 | 2015-05-28 | — | — | WO | disclosed |
| CN-104447740-A | Imidazolone derivative as well as drug composition and application thereof | BEIJING FORELAND BIOPHARMA CO LTD | 2015-03-25 | — | — | CN | disclosed |
| WO-2014079364-A1 | IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 北京富龙康泰生物技术有限公司 (CN) | 2014-05-30 | — | — | WO | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| EP-2616468-A1 | FUSED HETEROARYLS AND THEIR USES | Hutchison Medipharma Limited (CN) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304510-A1 | IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DMPK, MAP3K15, MAP4K2 | TXNRD1 4259/4885MAPT 2230/4885PIN1 419/4885 |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | FARS2, TIAL1, DHFR | TXNRD1 1722/4885MAPT 2577/4885PIN1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.